idil and its metabolites can be removed by hemodialysis.
Fluid retention and hypertrichosis are the most commonly occurring side effects of minoxidil. Hair regrowth in a patient with male pattern baldness was described in a case report of a hypertensive patient treated twice daily with 20 mg oral minoxidil. 6 The extensive hair regrowth continued after 10 months of therapy. New and increased hair growth as a side effect was also detected in an early clinical study involving five of eight patients on oral minoxidil therapy for 2 month^.^ Zappacosta' reported reversal of baldness in a patient on minoxidil for the treatment of hypertension.
After the third week of therapy with oral minoxidil, hypertrichosis usually appears between the eyebrows and the hair line, in the malar and temporal areas, on the backs of the arms, on the shoulders, and on the legs. Hair growth has been noted at all dose levels, although it appears later and is less marked after the smaller doses of 10 mg or less per day. New hair growth ceases abruptly when minoxidil therapy is discontinued, but the patient's appearance does not return to normal for several months. Normal hormonal assays were recorded in 50 patients who received minoxidil for 1 year or longer,'~~ and we do not believe that excessive hair growth is a result of an endocrine abnormality.
Overview of Efficacy and Safety
Dermal acute toxicity studies in rats have shown that minoxidil is not toxic when applied 10 mg/rat/ day and is slightly toxic at 30 mg/rat/day and 60 mg/rat/day. While no gross or microscopic lesions were found in the rat skin, the pharmacologic effects included dose-related decreases in hemoglobin, decreased erythrocyte counts, decreases in serum sodium and chloride levels, and increases in serum cholesterol and heart and liver weight. We are conducting the clinical research program for topical minoxidil slowly and with caution because of the potent action of the systemic formulation of minoxidil on the cardiovascular system in hypertensive patients. Initially, three 14-week studies involved daily bilateral applications of 1%, 3%, or 5% minoxidil to circular areas 2 cm in diameter on the scalps of patients with male pattern baldness. As expected, no systemic side effects were observed. There was some evidence of hair growth stimulation, appreciably delayed and variable in occurrence among patients.
Long-term clinical studies of 6-12 months were started in 1980 and 1981. Since then, several clinical studies have been completed and new ones started. For example, in one open-label study, we evaluated the effectiveness of twice-daily unoccluded applications of 5% minoxidil in men and women with alopecia areata and alopecia androgenetica. Therapy was scheduled for 6 months in alopecia areata and for 1 year in pattern baldness. Stimulation of hair growth ranged from minimal early evidence to appreciable restoration toward typical terminal scalp hair. It took 3-8 months to obtain the more definitive evidence of stimulated hair growth. Other investigators who used a topically applied solution of 1% minoxidil in three patients with alopecia areata unresponsive to conventional treatments found local hair regrowth in the area of application within 4-6 weeks in two of the patients."
Fenton and Wilkinson" induced hair growth in 22 of 30 (80.8%) patients with alopecia areata after 6 months of twice-daily topical applications of 1 Yo minoxidil lotion or ointment. Sixteen of these patients grew acceptable terminal hair.
In a double-blind study, Headington and Novak'* treated 21 healthy men with pattern baldness with twice-daily topical applications of 1 Yo or Soh minoxidil or the vehicle for minoxidil (water-propylene glycolalcohol). The shortest and longest hairs measured were recorded for each treatment site through study week 25 (Table 2) . Medications were applied only for 15.7 weeks (110 successive days), and no medication was applied during weeks 16-25. Results were expressed as the difference between an individual's minimum and maximum lengths of hair at baseline and at each evaluation period. A minimal increase in mean hair length was seen in all treatment groups, including the placebo group, between weeks 3-9 and at week 25. There were no statistically significant differences among the groups in the hair growth during the 12-week medication period. After 15.7 weeks of treatment in this study, clinical and statistical evaluations of the blood chemistries, CBC, urinalysis, and EKC were similar for subjects receiving the 1% or 5% solutions of minoxidil and those receiving the placebo vehicle, nor was there a difference between mean pre-and postmedication values in blood pressure, pulse rate, and body weights in these subjects. Mild stinging, burning, itching, and erythema were noted only after the evaluation at week 2 in 11 of 21 subjects (2 receiving 1% minoxidil, 4 receiving 5% minoxidil, and 5 receiving the vehicle). These effects were thought to be due to the vehicle.
Absorption and Excretion After Topical Minoxidil
In animal and human topical absorption studies, we have used I%, 3%, and 5% minoxidil in a propylene glycol-ethanol-water vehicle. When vehicles containing propylene glycol-alcohol-water were used, the in vitro transport data over 72 hours showed a cumulative penetration of 3.0 mg, 3.7 mg, and 4.0 mg of drug from the 1%, 3%, and 5% minoxidil solutions, respectively. The extent of percutaneous absorption in the rat and monkey, based upon the percentage of the applied dose of 14C-minoxidil excreted in the urine and stool, is shown in Table 3 . In the rat and monkey, the skin of the application sites retained 30-78% of the applied dose of ''C-minoxidil.
In ongoing clinical trials with topical minoxidil in patients with alopecia areata and alopecia androgenetica or both, we are using applications of 1%, 3%, and 5% minoxidil solutions once daily with or without overnight occlusion. After therapy ranging from a few months to 1 year in 150 patients, single-point and variable time values of serum minoxidil in six patients so tested at 2, 4, and 8 weeks tended to range from nondetectable levels (radioimmunoassay sensitivity of 1.4 ng/ml) to a maximum of 6.2 ng/ml. In a double-blind study of 21 men with pattern baldness,'* a radioimmunoassay with a sensitivity of 1.4 ng/ml showed no consistency or trend in minoxidil serum levels ( Table 4 ). The highest levels of minoxidil (6.2 ng/ml) occurred in the 5% minoxidil group at week 2. One subject in the 1% minoxidil group had a serum level of 2.3 ng/ml minoxidil at week 2.
In a percutaneous absorption/excretion study, 1 O/O or 5% solutions of ''C-minoxidil were applied topically to the scalps of 12 healthy men. At either dose, minoxidil was poorly absorbed through the skin. The mean recovery of the applied doses in the urine was less than 4% ( Table 5) . A fecal analysis was done in six of these volunteers and no radioactivity was detected. A mean of 4 3 4 5 % of the 1% and 5% applications of radioactive minoxidil was recovered from the surface of the skin ( Table 6 ). The total recovery of ''C-minoxidil in this study ranged from 42.9% to 47.2% for either dose at any of the test periods. We presume that the remaining material was lost from the surface of the skin to the environment. We evaluated the possibility that a portion of applied minoxidil is bound within the skin and slowly released to the systemic circulation, where it might be below the limits of detection used in this study. Biopsied tissue of the scalp from five patients 24 hours after the second treatment showed radioactivity
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Effect of Topical Minoxidil on Blood

Flow of the Scalp
Burton and c o -w~r k e r s '~, '~ postulated increased cutaneous perfusion with potent peripheral vasodilators. It has been suspected for a long time that localized hypertrichosis is associated with increased cutaneous blood flow in some cutaneous inflammatory conditions as well as with arteriovenous aneur y~m . '~-'~ In another double-blind study, we tested 0 0 ' 0 , 1%, 3%, and 5% randomly assigned solutions of minoxidil on the balding scalps of 16 human volunteers. On 2 consecutive days, an 0.25 ml volume of the formulations was uniformly spread over 100 cmz of the bald scalp. 
PPC).z'*zz
The 5% minoxidil solution increased blood flow when compared with the other treatments. As shown by LDV, on day 1 (Fig. 1) there was a statistically significant increase (p = 0.0001) in mean blood flow within 15 minutes of application; that flow was maintained at least through 1 hour. O n day 2 (Fig. 2) , blood flow stimulation increased (p = 0.0001) threefold within 15 minutes of application and remained that way for about 1 hour. With the photopulse plethysmography technique, the mean blood perfusion response was statistically significant (p = 0.01) only for application of the 5% minoxidil solution on day 2. Subject used hair drier several hours after treatment was applied
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In a double-blind study by Headington and Novak,12 a 1% or 5% minoxidil solution or placebo was applied twice daily to three groups of seven healthy men with pattern bladness. In all 21 patients, a 4-mm Baker disposable punch was used to obtain a biopsy from the vertex or from the parietal areas of the scalp pretreatment and at weeks 12 and 24.
Details of the histologic techniques used were published by H e a d i n g t~n .~~
Qualitative evaluation showed that biopsies obtained from individuals receiving either topical minoxidil or placebo did not differ from their pretreatment biopsies with respect to semiquantitative determination of inflammation. There was no suggestion of a direct toxic or irritant effect or of allergic contact dermatitis, nor was epidermal hyperplasia or dysplasia seen. The sebaceous epithelium and papillary reticular dermis appeared unaltered. Morphologic changes were not found in blood vessels, including vessels of the follicular dermal papillae. The seven subjects who received the 5% dose of minoxidil had a mean hair shaft diameter of 0.029 mm before treatment, which increased to 0.043 mm at 12 weeks and measured 0.042 mm at 24 weeks, although therapy was discontinued after 15.7 weeks. In this study, minoxidil and/or its vehicle affected hair growth by induction or hypertrophy of the existing follicles.
Quantitative data from this study show that we can determine from transverse sections of a scalp biopsy a patient's morphologic capability for response. The identification of potential morphologic nonresponders is, of course, essential to the study of topical stimulation of hair growth.
Comment
We are continuing an extensive program to evaluate the safety and efficacy of topical minoxidil in certain alopecias. In our studies to date, 1% and 5% solutions of topically applied minoxidil induced hair growth in some patients with alopecia areata (totalis, universalis) and alopecia androgenetica. The onset of stimulation of hair growth may be delayed 2-7 months, the stimulated hairs are pigmented, and the increase ranges from minimal to 3 cm or more. The positive hair growth stimulation seen to date in our studies is quite variable among patients. Some patients who applied topically the higher (5%) concentrations of minoxidil to the scalp showed hypertrichosis on the face and extremities, suggesting a systemic side effect.
The mechanism by which minoxidil stimulates hair growth is still unknown. 
